The factors involved in cell differentiation have recently garnered interest for their role in inhibition of pathogenesis in various tumors. However, their role in glioblastoma (GBM) remains poorly understood. We analyzed The Cancer Genome Atlas (TCGA) GBM data and found significant downregulation of neurogenic differentiation factor NeuroD2 in GBM patients. Low levels of NeuroD2 were found to be correlated with poor overall survival of GBM patients in TCGA dataset as well as in our cohort. Interestingly, NeuroD2 was shown to be transcriptionally induced by p53 and post-transcriptionally targeted by hypoxiainducible miRNA, miR-210. NeuroD2 overexpression diminished GBM aggressiveness by inhibiting cell proliferation, migration and promoting apoptosis under hypoxia. NeuroD2 overexpressing GBM cells failed to form three-dimensional (3D)-tumor spheroids and displayed reduced migration in a 3D gelatin matrix. NeuroD2 gene signature was enriched in pathways belonging to cytokine-cytokine receptor interaction, TNF-signaling, PI3K-AKT signaling, focal adhesion and ECM-receptor interaction. Overall, our study identifies a novel role of NeuroD2 as a tumor suppressor and prognostic biomarker in GBM the levels of which are tightly regulated by p53 and miR-210. Overexpressing NeuroD2 may potentially be a simple and efficient therapeutic strategy to inhibit the malignant phenotype of GBM cells.
Glioblastoma (GBM) is the most devastating tumor that accounts for about 15% of all primary brain tumors and about 60-75% of all astrocytomas.
1 GBM mainly arises de novo but sometimes can originate from low-grade astrocytoma. 1 GBMs have been categorized by the WHO as the Grade IV astrocytoma. 1 Hypoxia is a perilous feature of the glioma microenvironment and has been shown to be a negative prognostic factor. 2 Glioma stem cells are more commonly present in the hypoxic core of the tumor thus making these tumors highly incurable and prone to recurrence. 2 Hypoxia also hampers treatment by promoting aberrant angiogenesis making them inaccessible for chemo-and radiotherapy. 2 Thus, GBMs have a very poor prognosis with overall survival of 12-15 months. 2 Despite conventional treatment that includes surgery and radiotherapy followed by temozolomide treatment, survival time increases by only 1 year. 2 Thus, there is a crucial need to identify new therapeutic targets for treating GBM.
Our work here focuses on Neurogenins and neurogenic differentiation factors (NeuroDs) belonging to the bHLH family of transcription factors (TFs). Neurogenins are involved in neurogenesis and neural specification and further classified into Neurog1, 2 and 3. 3 NeuroDs are involved in the differentiation of nervous system and pancreas and further categorized into NeuroD1, D2, D4 and D6. 3 However, limited reports suggest the role of these TFs in abnormal cell growth or cancer. Previous reports of tumor-suppressive properties of Neurog2 in glioma prompted us to scrutinize the role of these TFs in GBM. [4] [5] [6] We performed The Cancer Genome Atlas (TCGA) GBM patient data analyses and identified that NeuroD2 and NeuroD6 exhibited strong downregulation, while the levels of other Neurogenins or NeuroDs remained minimally affected or unchanged. NeuroD2 displayed maximal downregulation in GBM patients as compared to control healthy individuals. NeuroD2 is overexpressed in male breast cancer and medulloblastoma, however, its causative role in these cancers has not yet been demonstrated. 7, 8 NeuroD2 has been shown to play a role in the determination and maintenance of neuronal cell fates.
Transcription Factor (REST), which is transcriptionally inhibited by NeuroD2 during neuronal differentiation, 9 works as an oncogenic controller in GBM stem cells. 10 Considering maximal downregulation of NeuroD2 in GBM patients and minimal reports on its functions in the aspect of tumor biology, we pursued to decipher its role in GBM with respect to its regulation and cellular functions.
Based on our findings, NeuroD2 appears as a tumor suppressor gene in GBM. NeuroD2 was found to be posttranscriptionally regulated by miR-210. Importantly, overexpression of NeuroD2 in hypoxic GBM cells impeded miR-210 mediated cell proliferation, migration, survival and threedimensional (3D)-tumor spheroid formation. Further, our results identified NeuroD2 to be a p53-regulated gene that promotes apoptosis in hypoxic condition. Assessment of its targetome revealed various genes involved in signaling pathways that are deregulated in GBM pathogenesis. In the context of clinical GBM biology, NeuroD2 showed downregulation in a grade-dependent manner and also appeared to be a novel prognostic marker in GBM patients. Overall, the work suggests NeuroD2 overexpression as an attractive therapy for GBM treatment.
Material and Methods

Cell lines and cellular assays
Detailed information on cell culture, transfections, luciferase assays, cell proliferation, soft agar, Boyden-Chamber, Caspase-3/7 activity, PE Annexin V apoptosis detection assay, generation of 3D-tumor spheroids and spheroid migration assay is summarized in Supporting Information Note 1.
Astrocytoma patient samples
Fifty samples of human GBM (WHO Grade IV), eight samples of anaplastic astrocytoma (GBM: WHO Grade III) and six samples of diffuse astrocytoma (GBM: WHO Grade II) were obtained from the Neuropathology Laboratory of the Department of Pathology, All India Institute of Medical Sciences (AIIMS), New Delhi, India. The study was approved by the ethical committee of the institute and written informed consent was obtained from the patients for the publication of this report and any accompanying images. Cases were selected on the basis of availability of adequate tumor tissue. The hematoxylin-and eosin-(H&E) stained slides of these cases were reviewed and a concordant agreement was established on the diagnosis between three trained pathologists, based on the WHO 2007 tumor classification. Clinical data, viz., age, sex and history were noted. The age range of the GBM patients was from 21 to 65 years, and the mean age was about 45 years. The male to female ratio was around 1.3. All cases were de novo primary GBMs. Five control brain tissues were also obtained from cases of epilepsy surgery. We used the epileptic tissue as non-neoplastic reference, as this serves as best control. We avoided the use of tissue adjacent to the tumor as control, since there is the possibility of tumor cell infiltration. TCGA dataset consisted of normal (n 5 10) and GBM (n 5 542) samples. The median age of patients was 59.6 years and male to female ratio was 1.6. The median overall survival was 13.9 months with 2 year survival of 22.5% and 5 year survival of 5.3%. REpository for Molecular BRAin Neoplasia DaTa (REMBRANDT) consisted of GBM (n 5 389), astrocytomas (n 5 122) and oligodendrogliomas (n 5 113) samples.
Additionally, gene expression analysis of NeuroD2 in GBM was performed by R2 software (http://hgserver1.amc.nl/ cgi-bin/r2/main.cgi) using GEO datasets namely GSE53733 (n 5 70), GSE43378 (n 5 50), GSE36245 (n 5 46) and normal cerebellum GSE7307 (n 5 9).
Construction of 3
0 -UTR-luciferase or promoter-luciferase constructs To determine whether miR-210 downregulates target transcripts through direct binding to the 3 0 -untranslated region (UTR), the fragment containing the miR-210 binding site in the 3 0 -UTR of NeuroD2 was PCR amplified and cloned into a luciferase reporter vector (pMIR-Report) downstream of a firefly luciferase gene. To further test whether the predicted target NeuroD2 is the direct target of miR-210, the miR-210 binding site in the 3 0 -UTR of the NeuroD2 gene was mutated by site-directed mutagenesis, and luciferase activity was determined. For p53 binding site analysis, upstream fragment of NeuroD2 promoter encompassing p53 binding site was cloned upstream of a luciferase promoter vector PGL3-TKluciferase (Promega, Madison, Wisconsin). All clones were confirmed by PCR, restriction digests and sequence analysis.
RNA and protein analyses
Details on RNA isolation, qRT-PCR and microarray expression profiling are provided in Supporting Information Note What's new? Factors that specify cell fate are implicated in the development of various tumor types. In the present study, neuronal differentiation 2 (NeuroD2), a transcriptional regulator involved in neuronal differentiation, was investigated for its significance in the halt and regression of glioblastoma (GBM). In GBM patients, NeuroD2 was found to be highly downregulated, with reduced expression correlated to poor prognosis. Its regulation was mediated by two key factors in GBM pathogenesis, p53 and miR-210. Meanwhile, NeuroD2 overexpression in hypoxic GBM cells inhibited cell proliferation, migration, and 3-D tumor spheroid formation. The findings identify NeuroD2 as a potential biomarker in GBM.
2, and details on ChIP-qPCR, IHC and western blotting are provided in Supporting Information Note 3.
Statistical analyses
All statistical analyses were carried out using the paired two tailed Student's t-test with Microsoft excel. For all analysis, pvalues 0.05 were considered as significant.
Results
Expression patterns of neurogenic differentiation factors in GBM patients and cell lines
We studied the expression patterns of the neurogenic differentiation factors in TCGA GBM patient datasets using betastasis software and validated their expression in GBM cell lines (U87MG and A172) using qRT-PCR ( Fig. 1 and Supporting Information 1A). We found that the levels of NeuroD1, NeuroD4 and Neurog3 remained unaltered in both GBM patients and cell lines (except NeuroD1 showed downregulation in A172). Neurog1 and 2 showed slight downregulation in the GBM patients, however, in the GBM cell lines these were found to be downregulated as compared to normal. Notably, NeuroD2 and NeuroD6 showed significant downregulation in all the GBM patient subtypes (classical, mesenchymal, proneural and neural) as compared to normal and also in the cell lines ( Fig. 1a and Supporting Information 1A). Since NeuroD2 showed maximal downregulation in both the patients and cell lines, we further focused our studies on it. The level of NeuroD2 was also checked in other GBM patient databases such as REMBRANDT and various GEO datasets. We observed that the levels of NeuroD2 were downregulated in different grades of glioma as compared to normal (Supporting Information 1B and 1C). We next determined NeuroD2 transcript levels by qRT-PCR in tumor tissues of Indian astrocytoma patients. In accordance to the TCGA/REMBRANDT/GEO datasets, we found that NeuroD2 transcript was downregulated in 38 out of 50 GBM samples as compared to normal controls (n 5 5; Fig. 1b ). We also found that its level was downregulated in a grade dependent manner (p 5 0.0179), being significantly decreased in high grade tumors (Grade II > Grade III> Grade IV; Fig. 1b ). Immunohistochemistry using NeuroD2 antibody also showed immunonegativity of NeuroD2 in 6/8 GBM patient samples as compared to normal brain tissues. A representative figure is shown in Supporting Information 2. Further we checked NeuroD2 expression in different grades of astrocytoma cell lines. For this, Grade III (SW1088 and GOS3) and Grade IV (U8MG and A172) cell lines were checked for NeuroD2 expression at protein level where a similar trend of NeuroD2 downregulation was obtained (Fig. 1c ) that inversely correlated with the grade. We further correlated NeuroD2 mRNA expression with the patient outcome using Kaplan-Meier survival analyses. Our results showed that patients with low NeuroD2 transcript levels showed poor prognosis in TCGA dataset ( Fig. 1d ) as well as in our cohort (Fig. 1e ).
MiR-210 targets NeuroD2 and shows inverse correlation of expression in GBM patients
We next studied the regulation of NeuroD2 in GBM patients. NeuroD2 locus was found to be altered in only 0.5-0.7% of GBM patients in different TCGA GBM datasets (Fig. 2a) . This suggested that NeuroD2 downregulation in GBM is not due to locus deletion or mutation. The promoter region (5KB upstream) of NeuroD2 was scanned for presence of CpG Island using DBCAT (DataBase of CpG islands and Analytical Tool) and a notable CpG island was found in NeuroD2 promoter region (Supporting Information 3A). Further, the cells were treated with 5-azacytidine, a demethylating agent and transcript levels of NeuroD2 were measured along with O 6 -methylguanine methyltransferase (MGMT) as a positive control. While the mRNA levels of MGMT were found to be induced upon 5-azacytidine treatment, the NeuroD2 transcript levels remained comparable to the untreated cells (Supporting Information 3B and 3C). This suggested that NeuroD2 may not be regulated by CpG DNA methylation in GBM. Since miRNAs play a major role in regulation of gene expression, we looked for the possibility of post-transcriptional regulation of NeuroD2 by miRNAs. We noticed that based on TargetScan software predictions, miR-210 showed the highest context score among all the miRNAs predicted to target NeuroD2 (Supporting Information 4). We checked the transcript levels of miR-210 in astrocytoma patients in TCGA datasets (Fig. 2b ) as well as in our cohorts ( Fig. 2c ) and found miR-210 to be highly expressed in GBM. Additionally, in contrast to NeuroD2, miR-210 showed higher expression in GBM as compared to low-grade diffuse or anaplastic astrocytoma (p 5 0.028). MiR-210 levels were also found to be significantly inversely correlated (Pearson correlation coefficient r 5 20.72) with NeuroD2, suggesting that in vivo concentration of NeuroD2 is dependent on the intrinsic level of miR-210 (Fig. 2d) . We then checked whether NeuroD2 is a direct target of miR-210. For this, miR-210 was transiently overexpressed or silenced in U87MG cell line and 48 hr posttransfection, NeuroD2 transcript levels were determined by qRT-PCR. Notably, NeuroD2 showed downregulation in response to miR-210 overexpression and vice versa (Fig. 2e) . To further validate the results from qRT-PCR, a 3 0 -UTR-luciferase reporter assay was performed using NeuroD2 3 0 -UTR construct with wild type or mutated miR-210 binding site (Fig. 2f) . A significant reduction in the luciferase activity of the NeuroD2-WT-3 0 -UTR was seen upon the overexpression of miR-210 while that of NeuroD2-mut-3 0 -UTR remained unaltered suggesting NeuroD2 to be a direct target of miR-210 (Fig. 2g) . Parallel effects were also seen at the protein level by western blotting. The glioma cells transfected with scramble or miR-210 mimic/ anti-miR-210 were analyzed for the expression of NeuroD2 protein using an antibody specific to NeuroD2. Inhibition of miR-210 resulted in increased levels of NeuroD2 protein while overexpression of miR-210 decreased the level of NeuroD2 (Fig. 2h) . These results strongly support the fact that NeuroD2 is posttranscriptionally regulated by miR-210. MiR-210 is a prominent
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hypoxia-inducible miRNA that has been shown to promote tumor aggressiveness. 11, 12 To know if miR-210 mediates regulation of other neurogenic differentiation factors, we modulated miR-210 levels under normoxia and hypoxia and scored for the levels of neurogenic differentiation factors. Interestingly, we found that miR-210 was found to specifically downregulate NeuroD1 and NeuroD2 levels under both normoxia and hypoxia, while the levels of other factors remained minimally affected except NeuroD4 which showed upregulation only under normoxia (Supporting Information 5). We then looked for miR-210 binding sites in NeuroD1 and NeuroD4, however, no miR-210 binding sites were observed suggesting an indirect mode of regulation of these factors.
NeuroD2 functions as a tumor suppressor under hypoxic conditions in GBM
Levels of NeuroD2 and miR-210 were found to be inversely correlated in vitro as well as in vivo. We thus, investigated the functional relevance of NeuroD2: miR-210 interactions under hypoxia and compared it with normoxia. We overexpressed NeuroD2 in two GBM cell lines, U87MG and A172, with or without miR-210 overexpression and performed the functional assays under both normoxia and hypoxia.
We found that NeuroD2 overexpression in GBM cells significantly inhibited cell survival, anchorage independence and migration under hypoxia (Figs. 3a-3c and Supporting Information 6) but not in normoxia (Figs. 3d-3f ). To check if NeuroD2 inhibited cellular effects are affected by upregulation of miR-210, NeuroD2 was transfected in GBM cells with or without miR-210 overexpression and subsequently scored for cellular assays. We found that in contrast to NeuroD2, miR-210 promotes cell proliferation, anchorage independence and migration under both normoxia and hypoxia and thus functions as an oncomiR (Figs. 3a-3f and Supporting Information 6). Interestingly, NeuroD2 mediated effects were partially inhibited when miR-210 was replenished in NeuroD2 
NeuroD2 inhibits 3D spheroid forming capacity of GBM cells
A growing body of evidence suggests the importance of 3D culture systems that more realistically simulate the effect of endogenous complex tumoral microenvironment in modeling of biological processes and discovery with in vivo relevance. 13 The ability of cancer cells to form 3D-tumor spheroids is directly linked to the tumorigenic potential of cancer cells and can be quantified. 13 GBM cells that were seeded in the Poly HEMA coated six-well plate, formed 3D spheroids. We first checked the levels of hypoxia marker genes, vascular endothelial growth factor (VEGF) and carbonic anhydrase 9 (CA9) that are known to be expressed in the cells forming the hypoxic core of tumor cells. 2 The levels of these marker genes were found to be high in U87MG and A172 cells grown as 3D spheroids as compared to 2D cells thus, supporting the development of a hypoxic core (Supporting Information 7).
We then generated 3D spheroids from U87MG cells transfected with NeuroD2 or control plasmid with or without miR-210 transfection. We observed that NeuroD2 overexpression severely affected the ability of the U87MG cells to form 3D spheroids suggesting its tumor suppressor nature (Figs. 4a and 4b ). NeuroD2 overexpression leads to the formation of loose aggregates with no proper spheroidal boundary. In contrast, miR-210 overexpressing cells made much larger 3D spheroids indicating it to be an oncomiR (Figs. 4a  and 4b ). The levels of hypoxia markers genes (VEGF and CA9) were also found to be higher in miR-210 overexpressing cells, suggesting that these cells formed spheroids with proper morphology and that miR-210 promoted the formation of hypoxic tumor core (Fig. 4c) . However, when NeuroD2 was overexpressed in the cells transfected with miR-210, the spheroids were substantially similar to the control spheroids suggesting that both miR-210 and NeuroD2 have contrasting roles in GBM, thus, nullifying their respective effects to the original level (Figs. 4a and 4b) . This was also reflected in the 3D migration assay in a gelatin matrix. A significantly higher migration was exhibited by the cells over expressing miR-210 which was severely inhibited by NeuroD2 coexpression (Figs. 4d and 4e ).
NeuroD2 is p53 regulated and promotes apoptosis under hypoxia in GBM
NeuroD2 was found to be upregulated by various stress conditions viz., serum starvation and treatment of chemo drugs such as doxorubicin and temozolomide in hypoxic conditions (Figs. 5a and 5b) but not in normoxia (Supporting Information 8A and 8B). These observations led us to inspect whether transcriptional regulation of NeuroD2 is p53 mediated under hypoxia. Since hypoxia-inducible factor 1A (HIF1A) and p53 both are mainly regulated at the protein level, we first decided to analyze the level of both by western blotting in normoxic and hypoxic conditions. As expected, HIF1A was robustly upregulated while p53 was marginally 8C) . Further, to determine the transcriptional regulation of NeuroD2, p53 binding sites were scanned in 5 kb upstream region of the transcriptional start site of this gene using program PROMO.
14 Interestingly, we found that upstream region of NeuroD2 was enriched in p53 binding sites (Fig. 5c and Supporting Information 9). To validate the in silico prediction, we transiently transfected p53 overexpressing plasmid in U87MG cells and maintained the cells in normoxic or hypoxic environment. After 48 hr of transfection, level of NeuroD2 was quantified by qRT-PCR. Upon overexpressing p53, NeuroD2 level remained unchanged under normoxia but showed 2-fold induction under hypoxia (Fig. 5d) . To further validate results from q-PCR, p53 binding sites (at least two sites with 100% similarity) were cloned in PGL3-TK-luciferase vector and luciferase reporter assay was performed in hypoxic condition. As expected, we saw a robust upregulation in luciferase activity, suggesting that p53 binding to NeuroD2 promoter leads to its upregulation (Fig. 5e) . To further confirm recruitment of p53 to the NeuroD2 promoter sites, we performed chromatin-immunoprecipitationqPCR assay. In agreement with the previous results, p53 showed strong binding (3.5-fold higher) to these sites (Fig. 5f) . The p53 binding sites in p21 and beta actin (ACTB) promoter were also studied as positive and negative control, respectively. These results strongly supported that NeuroD2 is transcriptionally induced by p53 in hypoxic microenvironment.
Since p53 is considered as a master guardian and executioner of apoptosis, 15 we next studied whether NeuroD2 also functions as a mediator of apoptosis. Apoptosis amendment was evaluated with Annexin V/7-AAD staining by FACS. Transfecting GBM cells with NeuroD2 induced a significant phosphatidylserine externalization that is the hallmark feature of early stages of apoptosis. These signals were readily detected by staining the cells with Annexin V-PE (Fig. 5g) . Next, to assess the effect of NeuroD2/miR-210 overexpression on the activity of Caspase-3/7 in glioma cells, Caspase-glo 3/ 7 assay was performed. Increased cleavage of Caspase-3/7, upon NeuroD2 overexpression, was detected by an increase in luminescent signals activity as compared to vehicle controls suggesting proapoptotic functions of NeuroD2 in GBM (Fig. 5h) . Contrasting results were seen on miR-210 overexpression suggesting miR-210 to be an antiapoptotic miRNA the effects of which are diminished by replenishment of NeuroD2 levels (Figs. 5g and 5h ).
NeuroD2 gene signature under hypoxia in GBM
Since NeuroD2 functions as a tumor suppressor under hypoxic conditions, we studied the genes affected by NeuroD2 overexpression under hypoxia by gene expression profiling using Affymetrix arrays. Genes showing >1.5-fold induction (p < 0.05) with respect to the vehicle control were considered to be differentially regulated. A total of 471 genes were found to be induced and expression of 616 genes was downregulated upon NeuroD2 overexpression. A list of differentially expressed genes along with their fold change is given in Supporting Information 10. Notably, the gene signature analyses using DAVID Bioinformatics Resources 6.8, 16 showed prevalence of numerous signaling pathways like TNF-signaling pathway (p 5 4.10 E -10), cytokine-cytokine receptor interaction (p 5 2.90 E -06), MAPK signaling pathway (p 5 2.00 E -03), pathways in cancer (p 5 1.10 E -02), TGF-b signaling pathway (p 5 1.80 E -02) and PI3K-Akt signaling pathway (p 5 2.10 E -02) showing important role of NeuroD2 in cellular signal transduction (Figs. 6a and 6b) .
NeuroD2 was found to modulate transcript level of several members of TNF-signaling, cytokine-cytokine receptor interaction, MAPK signaling pathway, etc. IL-24, BMP2, NFKBIA and LIF were the most upregulated genes showing robust upregulation in microarray and qRT-PCR results (Fig. 6c) . Though some members of the TNF-signaling and cytokine family such as CXCL8, IL6 and CSF2 were found to be downregulated or unchanged by qRT-PCR as opposed to their induction in microarray results, other members such as CXCL5 and IL1B were found to be upregulated in accordance to microarray results. NeuroD2 overexpression also brought about downregulation of the expression of numerous members of PI3K-Akt signaling, ECM-receptor interaction and focal adhesion pathways. These members include FN1, LAMA4, COL1A1, COL1A2 and COL5A2 (Fig. 6d) . Interestingly, the inhibitors of differentiation genes, ID1, ID2 and ID3 that are associated with TGF-b and signaling pathways regulating pluripotency of stem cells were also found to be downregulated. Thus, gene expression study coupled with pathway analysis and qRT-PCR strongly suggest the importance of NeuroD2 in various important signaling pathways in GBM.
Discussion
While the importance of neurogenic differentiation factor family in neurogenesis and neuronal differentiation has been well recognized, 3 their role and status in various cancers remained little explored. Here, we studied the expression pattern of the neurogenic differentiation factors in GBM and unraveled the regulation, functions and targets of NeuroD2, the most downregulated neurogenic differentiation factor in GBM.
NeuroD2 hails from the NeuroD family of neurogenic bHLH proteins. 3 It serves as a TF that induces transcription from specific promoters like GAP-43 promoter. 17 These promoters contain a consensus sequence (CANNTG), known as E-box. 17 As previously reported, ectopic expression of NeuroD2 along with a specific set of miRNAs can induce neurons from human fibroblasts.
18 NeuroD2 is also shown to be essential for amygdala, cortical development and emotional learning. 19 Beyond these classical features, there is very little known about NeuroD2 and its relation to tumor biology. A very recent report suggests NeuroD2 to be highly amplified along with neighboring genes GRB7 and IKZF3 in HER2 amplicon in male breast cancer. 7 Copy number gain of NeuroD2 was also found to be correlated with overall poor survival, high mitotic count and high tumor grade in male breast cancer. 7 Another report suggests that NeuroD2 is overexpressed in medulloblastomas. 8 In contrast, NeuroD2 was found to upregulate the expression of cyclin-dependent kinase inhibitor 1B (p27KIP1), a well-known tumor suppressor gene, that regulates the cell cycle progression at G1. 20 Our work here identifies a novel role of a neurogenic differentiation factor, NeuroD2 as tumor suppressor in GBM. This is the first report claiming the intrinsic low level of NeuroD2 in GBM patients and cell lines, correlating the low level with patient's poor survival and thus emphasizing its potential as a novel prognostic marker. A grade specific downregulation of NeuroD2 level was also seen in patients with astrocytic tumors. A recent article reported low levels of Neurog1/2 and NeuroD1 in GBM tumors and derived cultures. 5 However, on the basis of TCGA GBM data analyses, while levels of Neurog1/2 were found to be minimally downregulated in GBM patients, NeuroD1 levels show no change. NeuroD6 shows very low levels in GBM patients and cell lines generating curiosity regarding its role in GBM. NeuroD2 is shown here to be regulated at both transcriptional and post-transcriptional levels. We show that NeuroD2 is a stress inducible gene and that p53 brings about induction of NeuroD2 through binding to p53 binding sites in the NeuroD2 promoter. However, this induction was only observed under hypoxic conditions and not under normoxia. Binding of p53 to NeuroD2 promoter was also recently reported in human lung fibroblast cells undergoing neuronal differentiation. 21 In contrast to our results, it was shown that p53 by binding to NeuroD2 promoter brings about downregulation in NeuroD2 transcript levels and affects fibroblast-neuron conversion. 21 Thus, p53 mediated regulation of NeuroD2 seems tissue and context specific. We also found NeuroD2 to be regulated through miR-210 binding sites in its 3 0 -UTR. We show NeuroD2 as a direct miR-210 target. MiR-210 and NeuroD2 also show inverse correlation of expression in GBM patients. Thus, highly expressed miR-210 can be one of the reasons for low levels of NeuroD2 in GBM. This stands as first report on physical interaction of NeuroD2 with a miRNA. A functional synergistic interactions of NeuroD2 with miRNAs, miR-9/9* and miR-124 has been reported before in neuronal differentiation. 18 Deciphering NeuroD2 cellular functions in GBM revealed it to be a tumor suppressor gene involved in imparting decreased cell survival, migration, 3D-tumor spheroid formation and enhanced apoptosis under hypoxia. Previous reports including ours show that miR-210 behaves as an oncomiR by targeting tumor suppressors like GPD1L and HIF3A. 22, 23 Thus, it is conceivable that miR-210, through downregulation of NeuroD2, aggravates multiple hallmarks of cancer in the hypoxic microenvironment. Since NeuroD2 is a p53 inducible protein, it may also function as a mediator of p53 to induce apoptosis in GBM cells. Neurog2 too has been reported to play a tumor suppressor role in GBM by inducing cell death and cell cycle arrest of CD1331 or CD133-glioma stem cells. 5 While the role of other neuro-differentiation proteins have been reported in other cancers their role in GBM remains unexplored.
The dissection of the molecular mechanisms underlying various functions of NeuroD2 was done through documentation of its targets. NeuroD2 was found to upregulate transcript levels of IL-24, BMP2 and LIF. [24] [25] [26] Interestingly, previous reports of these factors show cancer specific growth suppressing and apoptosis inducing properties. NeuroD2 also suppresses the expression of proinflammatory cytokines such as CXCL8 and IL6 whereas increases the level of others such as CXCL5 and IL1B. Such kind of dual role of NeuroD2 to upregulate some cytokines and to downregulate the others needs to be investigated. PI3K-AKT pathway is known to be mutated in the majority of GBMs and is involved in the control of tumor growth and progression. 27 Up to 13 members of PI3K-AKT signaling pathway were found to be downregulated upon NeuroD2 overexpression. Several members of the gene family of collagen that are downregulated such as COL1A1, COL1A2 and COL5A1 are associated with cancer cell invasion and metastasis. 28 Numerous members of signaling pathways regulating pluripotency of stem cells and TGFb pathway (ID1, ID2 and ID3) were also found to be downregulated and are known to maintain CSCs and are responsible for the increased tumor aggressiveness. 29 Altogether it appears that NeuroD2 by regulation of pathways involved in tumor development or progression plays an important role in GBM biology. Overall, based on our findings, NeuroD2 emerges as a crucial participant in GBM biology. We also recognize NeuroD2 as critical mediator of cross talk between hypoxia and p53 signaling. NeuroD2 arises as a biomarker for astrocytoma grade determination and GBM patient prognosis. Further, it will be interesting to determine whether different grades of astrocytoma respond the same as GBM upon NeuroD2 expression and whether NeuroD2 overexpression interferes with the neural network of brain. Since NeuroD2 overexpression significantly inhibits GBM aggressiveness, we propose NeuroD2 as a novel promising target for GBM treatment.
